Urokinase expression and binding activity associated with the transforming growth factor β1-induced migratory and invasive phenotype of mouse epidermal keratinocytes

Journal of Cellular Biochemistry

Volumn 74, Issue 1, 1999, Pages 61-73

  Santibáñez, Juan F ^a,b   Frontelo, Pilar ^a   Iglesias, Maite ^a   Martínez, Jorge ^b   Quintanilla, Miguel ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Carcinogenesis; Invasiveness; Keratinocytes; Migration; TGF 1; UPA

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING SITE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL SPECIFICITY; CONTROLLED STUDY; ENZYME BINDING; KERATINOCYTE; MALIGNANT TRANSFORMATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; SKIN CARCINOMA;

ANIMALIA;

EID: 0343042204     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(19990701)74:1<61::AID-JCB7>3.0.CO;2-B     Document Type: Article

References (45)

1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. 1997. The urokinase-type plasminogen ativator system in cancer metastasis: a review. Int J Cancer 72:1-22.
2. Belin D, Vasalli JD, Combepine C, Godeau F, Nagamine Y, Reich E, Kocher HP, Duvoisin RM. 1985. Cloning, nucleotide sequence and expression of cDNAs encoding mouse urokinase-type plasminogen activator. Eur J Biochem 148:225-232.
3. Belin D, Wohlwend A, Schleuning W-D, Kruithof EKO, Vassalli J-D. 1989. Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2. EMBO J 8:3287-3294.
4. Boyer B, Tucker GC, Vallés AM, Franke WW, Thiery JP. 1989. Rearrangements of desmosomal and cytoskeletal proteins during the transition from epithelial to fibroblastoid organization in cultured rat bladder carcinoma cells. J Cell Biol 109:1495-1509.
5. Brückner A, Filderman AE, Kirchheimer JC, Binder BR, Remold HG. 1992. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell line A549 and Calu-1. Cancer Res 52:3042-3047.
6. Buchmann A, Ruggeri B, Klein-Szanto AJP, Balmain A. 1991. Progression of squamous carcinoma cells to spindle carcinomas of mouse skin is associated with an imbalance of H-ras alleles on chromosome 7. Cancer Res 51: 4097-4101.
7. Busso N, Masur SK, Lazega D, Waxman S, Ossowski L. 1994. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 126:259-270.
8. 1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype. Cell Growth Differ 6:1027-1035.
9. Caulín C, López-Barcons LI, González-Garrigues M, Navarro P, Lozano E, Rodrigo I, Gamallo C, Cano A, Fabra A, Quintanilla M. 1996. Suppression of the metastatic phenotype of a mouse skin carcinoma cell line independent of E-cadherin expression and correlated with reduced levels of Ha-ras oncogene products. Mol Care 15: 104-114.
10. 1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86: 531-542.
11. Degen SJ, Heckel JL, Reich E, Degen JL. 1987. The murine urokinase-type plasminogen activator gene. Biochemistry 26:8270-8279.
12. Díaz-Guerra M, Haddow S, Bauluz C, Jorcano JL, Cano A, Balmain A, Quintanilla M. 1992. Expression of simple epithelial cytokeratins in mouse epidermal keratinocytes harboring Harvey ras gene alterations. Cancer Res 52: 680-687.
13. Erickson L, Lawrence D, Loskutoff J. 1984. Reverse fibrin autography: a method and partially characterized protease inhibitors after dodecyl sulphate-polyacrilamide gel electrophoresis. Anal Biochem 137:456-463.
14. Estreicher A., Wohlwend A, Belin D, Schlenning WD, Vasalli J-D. 1989. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 264:1180-1189.
15. 1 induces squamous carcinoma cell variants with increased metastatic abilities and a disorganized cytoskeleton. Exp Cell Res 244:420-432.
16. 1 and TGF-α in primary keratinocytes and papillomas expressing v-Ha-ras. Mol Carc 4:210-219.
17. Glick AB, Kulkarni AB, Tennenbaum T, Hennings H, Flanders KC, O'Reilly M, Sporn MB, Karlsson S, Yuspa SH. 1993. Loss of expression of transforming growth factor β in skin and skin tumors is associated with hyperproliferation and a high risk for malignant coversion. Proc Natl Acad Sci USA 90:6076-6080.
18. 1 gene causes rapid progression to squamous cell carcinoma. Genes Dev 8:2429-2440.
19. Haddow S, Fowlis DJ, Parkinson K, Akhurst RJ, Balmain A. 1991. Loss of growth control by TGF-β occurs at a late stage of mouse skin carcinogenesis and is independent of ras gene activation. Oncogene 6:1465-1570.
20. Hay ED. 1993. Extracellular matrix alters epithelial differentiation. Curr Opin Cell Biol 5:1029-1035.
21. 1 antisense expression plasmid. Cell Growth Differ 6:1635-1642.
22. Hunter W, Greenwood FC. 1962. Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature 194:495-496.
23. Jeffers M, Rong S, Vande Woude GF. 1996. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16:1115-1125.
24. Keski-Oja J, Blasi F, Leof EB, Moses HL. 1988. Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-β. J Cell Biol 106:451-459.
25. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preisner KT, Ossovski L, Andreasen PA. 1997. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 232:420-429.
26. Lahio M, Keski-Oja J. 1992. Transforming growth factor-β as regulators of cellular growth and phenotype. Crit Rev Oncog 3:1-26.
27. Liu G, Shuman MA, Cohen RL. 1995. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 60:501-506.
28. Llorens A, Rodrigo I, López-Barcons L, González-Garrigues M, Lozano E, Vinyals A, Quintanilla M, Cano A, Fabra A. 1998. Down-regulation of E-cadherin in mouse skin carcinoma cells enhances a migratory and invasive phenotype linked to matrix metalloproteinase-9 gelatinase expression. Lab Invest 78:1131-1142.
29. Mansbridge JN, Hanawalt PC. 1988. Role of transforming growth factor beta in the maturation of human epidermal keratinocytes. J Inv Dermatol 90:336-341.
30. Massagué J. 1990. The transforming growth factor-β family. Annu Rev Cell Biol 6:597-641.
31. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S. 1996. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56:2428-2433.
32. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier V, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio M. 1992. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/ scatter factor. EMBO J 11:4825-4833.
33. Odekon LE, Sato Y, Rifkin DB. 1992. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol 150:258-263.
34. Odekon LE, Blasi F, Rifkin DB. 1994. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGF-β. J Cell Physiol 158:398-407.
35. 1 and Ha-ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10:2462-2477.
36. Planus E, Barlovatz-Meimon G, Rogers RA, Bonavaud S, Ingber DE, Wang N. 1997. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading. J Cell Sci 110:1091-1098.
37. Pollanen J, Saksela O, Salonen E-M, Andreasen P, Nielsen L, Dano K, Vaheri A. 1987. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 104:1085-1096.
38. Portella G, Liddell J, Crombie R, Haddow S, Clarke M, Stoler AB, Balmain A. 1994-95. Molecular mechanisms of invasion and metastasis during mouse skin tumor progression. Invas Metast 14:7-16.
39. Roskelley CD, Srebrow A, Bissell MJ. 1995. A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. Curr Opin Cell Biol 7:736-747.
40. Santibáñez JF, Maccioni RB, Martinez J. 1995. The secretion of urokinase-like plasminogen activator is inhibited by microtubule-interacting drugs. Cell Biochem Funct 13:217-225.
41. Stahl, A, Mueller BM. 1994. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 54:3066-3071.
42. Stefansson S, Lawrence DA. 1996. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin. Nature 383:441-443.
43. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. 1993. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541-573.
44. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. 1996. Regulation of integrin function by the urokinase receptor. Science 273:1551-1555.
45. Wrana JL, Attisano L, Cárcamo J, Zentella A, Doody J, Lahio M, Wang X-F, Massagué J. 1992. TGFβ signals through a heteromeric protein kinase receptor complex. Cell 71:1003-1014.